COMPANY

K36 Therapeutics

K36 Therapeutics developed KTX-1001 to provide a targeted therapy that specifically addresses the underlying cause of cancer for t(4;14) multiple myeloma patients. From company website Source · Oct 12, 2026

Keywords: cancer Myeloma Multiple Metastatic Castration-resistant Prostate Cancer Metastatic Castration-resistant Prostate Cancer, mCRPC mCRPC mCRPC (Metastatic Castration-resistant Prostate Cancer) KTX-2001

Profile checked Oct 10, 2026

2Trials (company is sponsor)

Timeline

Nov 21, 2025 Trial start Phase 1: A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001) source ↗
Feb 22, 2023 Trial start Phase 1: A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma source ↗

Upcoming milestones

2027-09 (ESTIMATED) · Phase 1 · A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001) · NCT07103018
Dec 31, 2027 (ESTIMATED) · Phase 1 · A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma · NCT05651932

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT05651932	A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma	Phase 1	Recruiting	Feb 22, 2023	Dec 31, 2027 (estimated)
NCT07103018	A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)	Phase 1	Recruiting	Nov 21, 2025	2027-09 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of Atlas Venture (captured Oct 12, 2026). portfolio page ↗